Genetic test aims to stop drug side effects before they start
NCT ID NCT06322238
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a genetic test can help doctors choose safer drugs and doses for 39 common medications. 66 adults getting a new prescription will receive the test, and researchers will track side effects like muscle aches, fainting, or mood changes for 48 weeks. The goal is to see if this approach reduces harmful drug reactions in everyday primary care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Pharmacogenetic (PGx) panel test
- What this could lead to
- If successful, this could show that a simple genetic test before prescribing common drugs reduces side effects and improves treatment in everyday primary care.
- What could go wrong
- This is a small, early-phase study at one health system, so results may not apply broadly. The test may not prevent all side effects, and some risks are still possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 66 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2024
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Inclusion Criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: 1. Subject must be ≥ 18 years old 2. Subject must receive a 1st prescription (meaning no known prescription for this drug in the preceding 12 months) for a drug included in Table 1, which is prescribed to them in routine primary care. 3. Subject is able and willing to take part and willing to be followed up on for 48 weeks 4. Subject is able to donate saliva 5. Subject has signed informed consent 6. Subject meets requirement for computer access implying computer literacy as measured by active use of the patient portal or their email Exclusion Criteria: 1. For the investigational arm only: Previous (direct-to-consumer, or clinical) pharmacogenomic testing that includes any of the genes included in the Focused Pharmacogenomics Panel 2. Pregnant or lactating (to be verbally confirmed with the patient) 3. Life expectancy estimated to be less than three months as determined by patient receiving hospice care 4. Duration of index drug total treatment length is planned to be less than seven consecutive days. 5. Current inpatients 6. Unable to consent to the study 7. Unwilling to take part 8. Subject has no permanent address 9. Subject has no current primary care provider 10. Subject is, in the opinion of the study coordinator after discussion with participating clinician/pharmacist/investigator, not suitable to participate in the study 11. Patient has a diagnosis of stage 4 or 5 chronic kidney disease (CKD) or is receiving dialysis 12. Patients with advanced liver failure (stage Child-Pugh C) or a diagnosis of liver cirrhosis 13. History of a liver transplant or an allogeneic hematopoietic stem cell transplant 14. DNA sample collected that requires retesting in the event that DNA collected was not sufficient for testing as determined by the laboratory
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Drug metabolism, poor, CYP2C19-related are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55902, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your DNA predict how you respond to a diabetes drug?
- Your DNA could determine if your birth control works
- Personalized dosing for kids with dystonia? new study investigates genetic factors
- ER genetic test aims to cut repeat trips to hospital
- Can a shorter bladder cancer treatment time cut side effects?
- Can your genes guide better depression treatment? new trial aims to find out.